20260212 chongqing runsheng pharma fda approved inhaler 1

“Chongqing-Made” Goes Global｜Chongqing’s Runsheng Pharma Gets FDA Approval for Self-Developed Inhaler, Entering US Market

12 February, 2026by Chongqing City

Chongqing-based Runsheng Pharma’s self-developed fluticasone propionate/salmeterol inhalation powder has received FDA approval, becoming the first Chinese enterprise to get FDA approval for an inhalation powder. The product treats asthma, developed over 12 years with over 1.2 billion yuan investment, passed FDA inspection with zero defects, and will benefit over 100 million asthma patients.